BTIG Assumes Innate Pharma at Buy, Announces Price Target of $8
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
BTIG analyst Jeet Mukherjee assumes Innate Pharma (NASDAQ:IPHA) with a Buy rating and announces Price Target of $8.
BTIG analyst Jeet Mukherjee assumes Innate Pharma (NASDAQ:IPHA) with a Buy rating and announces Price Target of $8.